



Figure S1. PD-L1 immunohistochemical expression results in two patients among the present study and matched with PD-L1 mRNA expression status [Magnification for positive quality control results in A and B: x40; magnification for other results in A and B: x200]. (A) Relative mRNA expression of PD-L1 was 2.13 (low mRNA expression). (B) Relatively mRNA expression of PD-L1 was 4.85 (high mRNA expression)]. PD-L1, programmed death ligand-1.

A Results




TPS results


Quality control sample results



Positive quality control results




CPS results




Negative quality control results

B Results



TPS results


Quality control sample results



Positive quality control results



CPS results



Negative quality control results

Figure S2. Progression-free survival of the 81 patients with advanced non-small cell lung cancer who received PD-1 blockades according to PD-L1 mRNA expression status. PD-L1, programmed death ligand-1.

	Chi-Square	df	Sig.
Log Rank (Mantel-Cox)	3.438	1	0.064

Test of equality of survival distributions for the different levels of g.




Figure S3. Overall survival of the 81 patients with advanced non-small cell lung cancer who received PD-1 blockades according to PD-L1 mRNA expression status. PD-L1, programmed death ligand-1.

	Chi-Square	df	Sig.
Log Rank (Mantel-Cox)	4.559	1	0.033

Test of equality of survival distributions for the different levels of g.

